| Dr Kevin E Boucher, DO | |
|
5 Clinic Rd, Abington, CT 06230-2005 | |
| (860) 974-0529 | |
| (860) 974-1029 |
| Full Name | Dr Kevin E Boucher |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 40 Years |
| Location | 5 Clinic Rd, Abington, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992869523 | NPI | - | NPPES |
| 4476899 | Other | CT | AETNA |
| 1770258-003 | Other | CT | CIGNA |
| WIP019 | Other | CT | OXFORD |
| 040000211CT-04 | Other | CT | ANTHEM BCBS |
| 051180 | Other | CT | HEALTHNET |
| 001002112 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 000211 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Day Kimball Hospital | Putnam, CT | Hospital |
| Westview Nursing Care & Rehab | Dayville, CT | Nursing home |
| Entity Name | Abington Family Healthcare, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871774034 PECOS PAC ID: 7719017177 Enrollment ID: O20100610000717 |
News Archive
"Children who live in households that own at least one insecticide-treated bed net (ITN) are less likely to be infected with malaria and less likely to die from the disease, according to a new study by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington," published today in PLoS Medicine, according to an IHME press release.
A new report launched to mark the start of M.E. Awareness Week 2005 calls on doctors to speed up the diagnosis of M.E./Chronic Fatigue Syndrome and so reduce the number of patients declining into long term ill health and disability. M.E. Diagnosis: Delay Harms Health is backed by an alliance of six national charities frustrated that delays in diagnosis are continuing to impair improvement or recovery in people with M.E.
More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet.
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin E Boucher, DO 5 Clinic Rd, Abington, CT 06230-2005 Ph: (860) 974-0529 | Dr Kevin E Boucher, DO 5 Clinic Rd, Abington, CT 06230-2005 Ph: (860) 974-0529 |
News Archive
"Children who live in households that own at least one insecticide-treated bed net (ITN) are less likely to be infected with malaria and less likely to die from the disease, according to a new study by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington," published today in PLoS Medicine, according to an IHME press release.
A new report launched to mark the start of M.E. Awareness Week 2005 calls on doctors to speed up the diagnosis of M.E./Chronic Fatigue Syndrome and so reduce the number of patients declining into long term ill health and disability. M.E. Diagnosis: Delay Harms Health is backed by an alliance of six national charities frustrated that delays in diagnosis are continuing to impair improvement or recovery in people with M.E.
More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet.
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
› Verified 4 days ago